No Data
Astrazeneca releases trial data on oral weight loss medication, with patients using the drug for four weeks experiencing nearly a 6% weight reduction.
①Astrazeneca reported that its oral small molecule weight loss drug AZD5004/ECC5004 reduced the average weight of patients by 5.8% within four weeks in early studies, and showed good tolerability; ② Astrazeneca acquired the global exclusive rights to the drug from Creentech for 2 billion US dollars last year, which is currently in the clinical research stage.
AstraZeneca (AZN) Gets a Sell From Deutsche Bank
AstraZeneca Says Obesity Pill Well Tolerated by Type-2 Diabetes Patients, Competitive
AstraZeneca's Promising Obesity Treatment Advances Justify Buy Rating: Analyst Report
Express News | Huaren pharmaceutical: Sodium Aescinate injection obtained Pharmaceutical registration certificate.
Futu Morning Post | Countdown to the election! The panic index VIX is burning high and uncertainty is haunting the market nerves; Up nearly 13% after hours! Palantir raises full-year revenue guidance
Jpmorgan warns: If Trump wins on Wednesday, the Fed may pause the easing cycle as early as December; Will the US stock market hit new highs after the election? Jpmorgan: FOMO psychology boosts, S&P may hit 6100 points by the end of the year; US polls: Harris and Trump are neck and neck in key 'swing states'.